{
    "Rank": 871,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT01167049",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "ML22199"
                },
                "Organization": {
                    "OrgFullName": "Peking University Cancer Hospital & Institute",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis",
                "OfficialTitle": "Neoadjuvant Chemotherapy With Xeloda in Combination With Paclitaxel in Gastric Cancer With Liver Metastasis"
            },
            "StatusModule": {
                "StatusVerifiedDate": "July 2010",
                "OverallStatus": "Unknown status",
                "LastKnownStatus": "Recruiting",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "August 2009"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "December 2013",
                    "PrimaryCompletionDateType": "Anticipated"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "December 2013",
                    "CompletionDateType": "Anticipated"
                },
                "StudyFirstSubmitDate": "July 21, 2010",
                "StudyFirstSubmitQCDate": "July 21, 2010",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "July 22, 2010",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "July 21, 2010",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "July 22, 2010",
                    "LastUpdatePostDateType": "Estimate"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyOldNameTitle": "Ji Jiafu/professor",
                    "ResponsiblePartyOldOrganization": "Beijing Cancer Hosptial"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Peking University Cancer Hospital & Institute",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "Roche Pharma AG",
                            "CollaboratorClass": "INDUSTRY"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "To investigate the efficacy of capecitabine combined with paclitaxel as neoadjuvant chemotherapy for gastric cancer with liver metastasis only",
                "DetailedDescription": "Patients with advanced or metastatic gastric cancer have a poor prognosis. The optimal treatment of gastric cancer with liver metastases without other distant metastases remains a matter for debate and there are few prospective clinical trials to explore this area. The aim of this prospective phase II study is to evaluate the optimal treatment of gastric cancer with liver metastases.\n\nIn preclinical xenograft models, capecitabine was highly active against several tumors, including breast, colorectal, gastric, and cervical tumors, and against both 5-FU-sensitive and 5-FU-resistant tumors. Intermittent capecitabine (1250 mg/m2 daily dose for 14 days, followed by a 7-day rest period) was shown to be active as a single agent in previously untreated AGC patients, with a response rate of 28.2% in 39 patients. The combination of capecitabine with other drugs, such as cisplatin, oxaliplatin, epirubicin, and docetaxel, had an objective response rate of 40-68% as first-line treatment in patients with AGC.\n\nIn human colon cancer xenograft model, thymidine phosphorylase is upregulated and synergy between paclitaxel and capecitabine has been observed. The activity of capecitabine in patients with breast cancer refractory to paclitaxel and anthracyclines suggests that the combination of capecitabine and paclitaxel may be effective in treating patients with advanced breast cancer. Doses recommended are capecitabine 1650 mg/m2 per day orally for 14 days and paclitaxel 175 mg/m2 i.v. every 3 weeks.\n\nIn a phase II trial with 45 patients involved, 2 patients showed complete response and 20 showed partial response making the overall response rate 48.9% (95%CI:30.3-63.5%). There was no neutropaenic fever or treatment-related deaths. That study demonstrated that paclitaxel and capecitabine combination chemotherapy was active and highly tolerable.\n\nThe rationale of this study was to find out if outcome could be improved after neoadjuvant chemotherapy with paclitaxel and capecitabine with or without local treatment for patients without other distant metastasis than liver metastasis."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Gastric Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "gastric cancer with liver metastasis"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "Non-Randomized",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "60",
                    "EnrollmentType": "Anticipated"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "CAPECITABINE",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Single arm:\n\nCapecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; repeat three cycles (approximately 3- months);",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: CAPECITABINE"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "CAPECITABINE",
                            "InterventionDescription": "Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; Repeat three cycles (approximately 3- months);",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "CAPECITABINE"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Xeloda"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Tumor response will be evaluated using RECIST criteria. Survival data will be analyzed by Kaplan Meier method. 95% CI will be provided",
                            "PrimaryOutcomeDescription": "Primary Endpoint is PFS (progression free survival), tumor response will be evaluated using RECIST criteria. Survival data will be analyzed by Kaplan Meier method. 95% CI will be provided.",
                            "PrimaryOutcomeTimeFrame": "3 years from last patient enrolled"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nAmbulatory males or females, aged no less than 18 years.\nECOG performance status: 0-1.\nHistologically confirmed gastric adeno-carcinoma.\nRadiologically confirmed liver metastasis without other distant metastasis.\nNo serious concomitant medical illnesses\nLife expectancy more than 3 months\nBe willing and able to comply with the protocol for the duration of the study\nNo Prior treatment for metastatic disease\nGive signed informed consent\n\nExclusion Criteria:\n\nnot fit for the inclusion criteria\nnot able to comply with the protocol\nwith high risks which may compromise the benefit of proposed regimen\nActive (significant or uncontrolled) gastrointestinal bleeding",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "CentralContactList": {
                    "CentralContact": [
                        {
                            "CentralContactName": "Jiafu Ji, Post-Doctor",
                            "CentralContactRole": "Contact",
                            "CentralContactPhone": "86 21 88196048",
                            "CentralContactEMail": "jiafuj@hotmail.com"
                        }
                    ]
                },
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Jiafu Ji, Post-Doctor",
                            "OverallOfficialAffiliation": "Peking University Cancer Hospital & Institute",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Beijing Cancer Hospital",
                            "LocationStatus": "Recruiting",
                            "LocationCity": "Beijing",
                            "LocationState": "Beijing",
                            "LocationZip": "100036",
                            "LocationCountry": "China",
                            "LocationContactList": {
                                "LocationContact": [
                                    {
                                        "LocationContactName": "Aiwen Wu, MD",
                                        "LocationContactRole": "Contact",
                                        "LocationContactPhone": "86 10 88196050",
                                        "LocationContactEMail": "wuaw@sina.com"
                                    }
                                ]
                            }
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000009362",
                            "ConditionMeshTerm": "Neoplasm Metastasis"
                        },
                        {
                            "ConditionMeshId": "D000013274",
                            "ConditionMeshTerm": "Stomach Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009385",
                            "ConditionAncestorTerm": "Neoplastic Processes"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000010335",
                            "ConditionAncestorTerm": "Pathologic Processes"
                        },
                        {
                            "ConditionAncestorId": "D000005770",
                            "ConditionAncestorTerm": "Gastrointestinal Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000004067",
                            "ConditionAncestorTerm": "Digestive System Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000004066",
                            "ConditionAncestorTerm": "Digestive System Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000005767",
                            "ConditionAncestorTerm": "Gastrointestinal Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000013272",
                            "ConditionAncestorTerm": "Stomach Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M11997",
                            "ConditionBrowseLeafName": "Neoplasm Metastasis",
                            "ConditionBrowseLeafAsFound": "Metastases",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M15754",
                            "ConditionBrowseLeafName": "Stomach Neoplasms",
                            "ConditionBrowseLeafAsFound": "Gastric Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M12020",
                            "ConditionBrowseLeafName": "Neoplastic Processes",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8576",
                            "ConditionBrowseLeafName": "Gastrointestinal Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M6946",
                            "ConditionBrowseLeafName": "Digestive System Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M6945",
                            "ConditionBrowseLeafName": "Digestive System Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8573",
                            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15752",
                            "ConditionBrowseLeafName": "Stomach Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T5486",
                            "ConditionBrowseLeafName": "Stomach Cancer",
                            "ConditionBrowseLeafAsFound": "Gastric Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC06",
                            "ConditionBrowseBranchName": "Digestive System Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "Rare",
                            "ConditionBrowseBranchName": "Rare Diseases"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000069287",
                            "InterventionMeshTerm": "Capecitabine"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000964",
                            "InterventionAncestorTerm": "Antimetabolites, Antineoplastic"
                        },
                        {
                            "InterventionAncestorId": "D000000963",
                            "InterventionAncestorTerm": "Antimetabolites"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        },
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M19227",
                            "InterventionBrowseLeafName": "Paclitaxel",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M231",
                            "InterventionBrowseLeafName": "Albumin-Bound Paclitaxel",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M377",
                            "InterventionBrowseLeafName": "Capecitabine",
                            "InterventionBrowseLeafAsFound": "Ultrasound",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M10800",
                            "InterventionBrowseLeafName": "Liver Extracts",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3971",
                            "InterventionBrowseLeafName": "Antimetabolites",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "Hemat",
                            "InterventionBrowseBranchName": "Hematinics"
                        }
                    ]
                }
            }
        }
    }
}